ABBV’s MALACHITE-1/2 studies comparing V-Pak to Incivek (#msg-94927196) would never have completed enrollment if the trial sites had been in the US and EU.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.